Lesson plan
KB-128
KB-128 is a serotonin 5-HT 2 receptor modulator which is under development for the treatment of alcoholism (alcohol use disorder). Its route is unspecified. The drug acts as a biased agonist of the serotonin 5-HT 2C receptor, with high G q protein bias and minimal or negligible β-arrestin recruitment. It additionally acts as a silent antagonist of the serotonin 5-HT 2A and 5-HT 2B receptors. Due to its lack of activation of the serotonin 5-HT 2A and 5-HT 2B receptors, KB-128 is expected to lack hallucinogenic activity and cardiac valvulopathy risk, respectively. The drug has been reported to reduce alcohol consumption in rodents. It is being studied in terms of influence on methamphetamine-induced hyperactivity in rodents as well. KB-128 is under development by Küleon Bioscience (formerly Psilosterics). It was first described by 2023. As of November 2025, the drug is in the preclinical research stage of development for treatment of alcoholism. There is also interest in KB-128 for potential treatment of various other conditions, including schizophrenia, Alzheimer's disease psychosis, depression, other addictions like stimulant use disorder, and obesity. KB-128 is listed on Psychedelic Alpha's drug development tracker and hence may be related to serotonergic psychedelics.…
Article summary
KB-128 is a serotonin 5-HT 2 receptor modulator which is under development for the treatment of alcoholism (alcohol use disorder). Its route is unspecified. The drug acts as a biased agonist of the serotonin 5-HT 2C receptor, with high G q protein bias and minimal or negligible β-arrestin recruitment. It additionally acts as a silent antagonist of the serotonin 5-HT 2A and 5-HT 2B receptors. Due to its lack of activation of the serotonin 5-HT 2A and 5-HT 2B receptors, KB-128 is expected to lack hallucinogenic activity and cardiac valvulopathy risk, respectively. The drug has been reported to reduce alcohol consumption in rodents. It is being studied in terms of influence on methamphetamine-induced hyperactivity in rodents as well. KB-128 is under development by Küleon Bioscience (formerly Psilosterics). It was first described by 2023. As of November 2025, the drug is in the preclinical research stage of development for treatment of alcoholism. There is also interest in KB-128 for potential treatment of various other conditions, including schizophrenia, Alzheimer's disease psychosis, depression, other addictions like stimulant use disorder, and obesity. KB-128 is listed on Psychedelic Alpha's drug development tracker and hence may be related to serotonergic psychedelics.…
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.